Country: European Union
Language: English
Source: EMA (European Medicines Agency)
Tremelimumab
AstraZeneca AB
L01FX20
tremelimumab
Antineoplastic agents
Carcinoma, Hepatocellular
Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).Imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.
Revision: 2
Authorised
2023-02-20
38 B. PACKAGE LEAFLET 39 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT IMJUDO 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION tremelimumab This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor. If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What IMJUDO is and what it is used for 2. What you need to know before you are given IMJUDO 3. How you are given IMJUDO 4. Possible side effects 5. How to store IMJUDO 6. Contents of the pack and other information 1. WHAT IMJUDO IS AND WHAT IT IS USED FOR IMJUDO is an anti-cancer medicine. It contains the active substance tremelimumab, which is a type of medicine called a _monoclonal antibody._ This medicine is designed to recognise a specific target substance in the body. IMJUDO works by helping your immune system fight your cancer. IMJUDO in combination with durvalumab is used to treat a type of liver cancer, called advanced or unresectable hepatocellular carcinoma (HCC). It is used when your HCC: cannot be removed by surgery (unresectable), and may have spread within your liver or to other parts of the body. IMJUDO is used to treat a type of lung cancer called advanced non-small cell lung cancer in adults. It will be used in combination with other anti-cancer medicines (durvalumab and chemotherapy). As IMJUDO will be given in combination with other anti-cancer medicines, it is important that you also read the package leaflet for these other medicines. If you have any questions about these medicines, ask your doctor. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE G Read the complete document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT IMJUDO 20 mg/ml concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of concentrate for solution for infusion contains 20 mg of tremelimumab. One vial of 1.25 ml of concentrate contains 25 mg of tremelimumab. One vial of 15 ml of concentrate contains 300 mg of tremelimumab. Tremelimumab is a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) immunoglobulin G2 IgG2a monoclonal antibody produced in murine myeloma cells by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). Clear to slightly opalescent, colourless to slightly yellow solution, free from or practically free from visible particles. The solution has a pH of approximately 5.5 and an osmolality of approximately 285 mOsm/kg. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS IMJUDO in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). IMJUDO in combination with durvalumab and platinum-based chemotherapy is indicated for the first- line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment must be initiated and supervised by a physician experienced in the treatment of cancer. Posology The recommended dose of IMJUDO is presented in Table 1. IMJUDO is administered as an intravenous infusion over 1 hour. 3 TABLE 1. RECOMMENDED DOSE OF IMJUDO INDICATION RECOMMENDED IMJUDO DOSAGE DURATION OF THERAPY Advanced or unresectable HCC IMJUDO 300 mg a as a single dose adminis Read the complete document